Hematopoietic progenitor cell mobilization with “just-in-time” plerixafor approach is a cost-effective alternative to routine plerixafor useLauren Veltri, Abraham S. Kanate, Aaron Cumpston et al.|Cytotherapy|2015Cited by 33
Impact of the duration of antiviral prophylaxis on rates of varicella-zoster virus reactivation disease in autologous hematopoietic cell transplantation recipientsQuoc Truong, Aaron Cumpston, Lauren Veltri et al.|Annals of Hematology|2013Cited by 22
Pre-existing cardiovascular disease increases risk of atrial arrhythmia and mortality in cancer patients treated with IbrutinibJuan Carlo Avalon, Brijesh Patel, Jacob Fuqua et al.|Cardio-Oncology|2021Cited by 19
Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin LymphomaBinod Dhakal, Mehdi Hamadani, Abraham S. Kanate et al.|Transplantation and Cellular Therapy|2016Cited by 8
Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients with Relapsed/Refractory Acute Myeloid LeukemiaBrandi Anders, Aaron Cumpston, Lauren Veltri et al.|Advances in Hematology|2017Cited by 6